Appendix 4E and 2026 Annual Report
Filed with ASX · · 118 pages · English
Alterity Therapeutics Ltd. on 6ix
Story so far
Earlier from Alterity Therapeutics
- Alterity Therapeutics Announces Granting of New U.S. Composition of Matter Patent for ATH434
- Granted New U.S. Composition of Matter Patent for ATH434
- Alterity Therapeutics Releases Appendix 4C – Q4 FY26 Quarterly Cash Flow Report & Corporate Update
- Alterity Therapeutics to Participate in the Virtual BTIG Biotechnology Conference 2026
- ATH Receives A$3.98m R&D Tax Incentive
Later from Alterity Therapeutics
- $4.2M Options Underwriting Agreement Executed
- Alterity Therapeutics to Participate in a Fireside Chat at the Cantor Global Healthcare Conference 2026
- Alterity Therapeutics Presents New Analyses of ATH434 Phase 2 Data in Multiple System Atrophy at the 2026 International Congress of Parkinson’s Disease and Movement Disorders
- Quarterly Activities/Appendix 4C Cash Flow Report
Follow Alterity Therapeutics into a list and get an email when it puts out news.
Follow Alterity Therapeutics